Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Exclusion Criteria

• •Laboratory values of:
• •* Platelet count \< 30,000/µL
• •* AST or ALT \> 2 x ULN (upper limit of normal)
• •* Total bilirubin \> 2 x ULN
• •* Creatinine \> 2 mg/dL
• •Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids (\> 10 mg oral prednisone or equivalent), or systemic biologic anticancer therapy within 21 days before beginning study treatment
• •Major surgery or hospitalization for a serious illness within the last 3 months
• •Greater than three prior regimens (where a regimen is defined as a treatment for CLL/SLL given initially or after disease progression)
• •Prior malignancy requiring current or prior treatment within the past 5 years, except for cervical neoplasia in situ and non-melanomatous skin cancer
• •Uncontrolled hypertension